New Lung Cancer Drug Study Leaves Mesothelioma Patients Hopeful

Last week concluded the annual Washington D.C. conference of the American Association for Cancer Researchers (AACR). At the conference, scientists and researchers from around the world reported their most recent breakthroughs and innovations for various forms of cancer.

One of the stand out presentations for the week included Bristol-Myers Squib drug in first phase clinical trials called Opdivo (MDX-1106). The drug increased the five year survival for some patients with non-small cell lung cancer to 16% from the National Cancer’s Institute’s rate of 4.9%. To read the whole study click here.

Opvido operates by blocking the PD-L1 protein and leading the immune system to fight the cancerous cells. This type of treatment protocol also is a signature of fighting pleural mesothelioma. The results are very promising for other types of cancers including asbestos related ones.

Dr. Brahmer stated that, “We are performing further studies to learn why these patients did so well for so long and better understand which patients can stop treatment at two years and which of them need to continue treatment beyond two years.”

The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.

Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers.